Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials

Journal of the American College of Cardiology

Volumn 64, Issue 5, 2014, Pages 485-494

  Boekholdt, S Matthijs ^a   Hovingh, G Kees ^a   Mora, Samia ^b   Arsenault, Benoit J ^a   Amarenco, Pierre ^c   Pedersen, Terje R ^d   Larosa, John C ^e   Waters, David D ^f   Demicco, David A ^g   Simes, R John ^h   Keech, Antony C ^h   Colquhoun, David ⁱ   Hitman, Graham A ^j   Betteridge, D John ^k   Clearfield, Michael B ^l   Downs, John R ^m,n   Colhoun, Helen M ^o   Gotto Jr , Antonio M ^p   Ridker, Paul M ^b   Grundy, Scott M ^q   Kastelein, John J P ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BICHAT HOSPITAL   (France)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PFIZER INC   (United States)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ WESLEY HOSPITAL   (Australia)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^l TOURO UNIVERSITY CALIFORNIA   (United States)

^m UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁿ SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^o UNIVERSITY OF DUNDEE   (United Kingdom)

^p WEILL CORNELL MEDICAL COLLEGE   (United States)

^q UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

apolipoprotein B; LDL cholesterol; meta analysis; non HDL cholesterol

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG DOSE INCREASE; DRUG MEGADOSE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; INDIVIDUALIZATION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

APOLIPOPROTEIN B; LDL-CHOLESTEROL; META-ANALYSIS; NON-HDL-CHOLESTEROL;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPOPROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WORLD HEALTH;

EID: 84905189482     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.02.615     Document Type: Article

References (34)

1. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. T.R. Pedersen, A.G. Olsson, and O. Faergeman et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460
3. R.J. Simes, I.C. Marschner, and D. Hunt et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105 2002 1162 1169
4. S.D. Wiviott, C.P. Cannon, and D.A. Morrow et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 46 2005 1411 1416
5. J.C. LaRosa, S.M. Grundy, and J.J. Kastelein et al. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study) Am J Cardiol 100 2007 747 752
6. J. Hsia, J.G. MacFadyen, and J. Monyak et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
7. S.M. Boekholdt, B.J. Arsenault, and S. Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
8. R.P. Giugliano, N.R. Desai, and P. Kohli et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
9. E.M. Roth, J.M. McKenney, and C. Hanotin et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
10. G.S. Thomas, W.C. Cromwell, and S. Ali et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized double-blind placebo-controlled trial J Am Coll Cardiol 62 2013 2178 2184
11. A.P. Verhagen, H.C. de Vet, and R.A. de Bie et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus J Clin Epidemiol 51 1998 1235 1241
12. D. Moher, A. Liberati, and J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
13. J.P. Higgins, S.G. Thompson, and J.J. Deeks et al. Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
14. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
15. J.R. Downs, M. Clearfield, and S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
16. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
17. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
18. J.C. LaRosa, S.M. Grundy, and D.D. Waters et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
19. T.R. Pedersen, O. Faergeman, and J.J. Kastelein et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
20. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
21. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
22. M.H. Davidson, K.C. Maki, and T.A. Pearson et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am J Cardiol 96 2005 556 563
23. J.A. Simon, F. Lin, and S.B. Hulley et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study Am J Cardiol 97 2006 843 850
24. D. Hunt, P. Young, and J. Simes et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial Ann Intern Med 134 2001 931 940
25. C.L. Shear, F.A. Franklin, and S. Stinnett et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins Circulation 85 1992 1293 1303
26. R.C. Pasternak, S.C. Smith Jr., and C.N. Bairey-Merz et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins J Am Coll Cardiol 40 2002 567 572
27. B. McGinnis, K.L. Olson, and D. Magid et al. Factors related to adherence to statin therapy Ann Pharmacother 41 2007 1805 1811
28. M.R. DiMatteo, H.S. Lepper, and T.W. Croghan Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence Arch Intern Med 160 2000 2101 2107
29. D.I. Chasman, D. Posada, and L. Subrahmanyan et al. Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2004 2821 2827
30. J.F. Thompson, C.L. Hyde, and L.S. Wood et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort Circ Cardiovasc Genet 2 2009 173 181
31. D.I. Chasman, F. Giulianini, and J. MacFadyen et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial Circ Cardiovasc Genet 5 2012 257 264
32. D. Voora, S.H. Shah, and C.R. Reed et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response Circ Cardiovasc Genet 1 2008 100 106
33. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
34. J. Perk, G. De Backer, H. Gohlke The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 33 2012 1635 1701